GE HealthCare Technologies (GEHC) Financials: History & Chart

GE HealthCare Technologies Inc. (GEHC)GEHCGE HealthCare Technologies Inc.

About GE HealthCare Technologies Inc.

GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.

Chicago, IL

54,000 employees

www.gehealthcare.com

Healthcare / Medical - Healthcare Information Services

Sector: Healthcare
Industry: Medical - Healthcare Information Services
CEO: Peter J. Arduini

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	20.24B	5.29B	5.13B	4.67B	5.14B	5.01B	4.78B	5.32B	4.86B
Cost of Goods Sold	11.56B	3.12B	3.15B	2.13B	3.15B	3.02B	2.77B	3.04B	2.84B
Gross Profit	8.69B	2.18B	1.98B	2.54B	1.99B	1.99B	2.01B	2.27B	2.03B
Gross Profit Margin	42.9%	41.2%	38.5%	54.3%	38.7%	39.7%	42.1%	42.8%	41.7%
Total Operating Expenses	6.12B	1.44B	1.46B	1.88B	1.34B	1.33B	1.38B	1.47B	1.35B
Research & Development	1.32B	323.00M	345.00M	362.00M	292.00M	302.00M	344.00M	344.00M	316.00M
Selling, General & Administrative	4.32B	1.12B	1.12B	1.04B	1.04B	1.03B	1.04B	1.13B	1.03B
Operating Income (EBIT)	2.57B	739.00M	515.00M	664.00M	653.00M	654.00M	629.00M	801.00M	676.00M
Operating Margin	12.7%	14.0%	10.0%	14.2%	12.7%	13.1%	13.2%	15.1%	13.9%
Income Before Tax (EBT)	2.04B	693.00M	505.00M	202.00M	643.00M	613.00M	692.00M	834.00M	658.00M
Interest Income	-6.00M	N/A	N/A	-18.00M	12.00M	6.00M	N/A	N/A	5.00M
Interest Expense	436.00M	114.00M	96.00M	103.00M	123.00M	113.00M	111.00M	111.00M	130.00M
Other Income/Expense	-528.00M	-46.00M	-10.00M	-462.00M	-10.00M	-41.00M	63.00M	33.00M	-18.00M
Net Income	1.59B	573.00M	389.00M	184.00M	446.00M	486.00M	564.00M	720.00M	471.00M
Income Tax Expense	446.00M	119.00M	94.00M	54.00M	179.00M	113.00M	104.00M	96.00M	168.00M
Net Profit Margin	7.9%	10.8%	7.6%	3.9%	8.7%	9.7%	11.8%	13.5%	9.7%
EBITDA	3.58B	899.00M	668.00M	1.21B	801.00M	802.00M	765.00M	941.00M	819.00M
EBITDA Margin	17.7%	17.0%	13.0%	25.9%	15.6%	16.0%	16.0%	17.7%	16.8%
Depreciation & Amortization	1.01B	160.00M	153.00M	548.00M	148.00M	148.00M	136.00M	140.00M	143.00M
EPS Basic	3.48	1.24	0.85	0.41	0.98	1.06	1.23	1.58	1.03
EPS Diluted	3.45	1.24	0.85	0.38	0.98	1.06	1.23	1.57	1.02
Shares Outstanding	453.00M	453.00M	456.00M	456.52M	456.00M	457.00M	457.00M	457.00M	457.00M
Diluted Shares Outstanding	454.00M	454.00M	457.00M	460.27M	457.00M	458.00M	459.00M	459.00M	459.00M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Revenue	20.63B	19.67B	19.55B	18.34B	17.59B	17.16B	16.63B
Cost of Goods Sold	12.38B	11.47B	11.63B	11.16B	10.41B	10.40B	10.09B
Gross Profit	8.25B	8.21B	7.92B	7.18B	7.17B	6.77B	6.55B
Gross Profit Margin	40.0%	41.7%	40.5%	39.1%	40.8%	39.4%	39.4%
Total Operating Expenses	5.49B	5.58B	5.49B	4.66B	4.38B	4.05B	4.42B
Research & Development	1.26B	1.31B	1.21B	1.03B	816.00M	810.00M	833.00M
Selling, General & Administrative	4.22B	4.27B	4.28B	3.63B	3.56B	3.24B	3.59B
Operating Income (EBIT)	2.76B	2.63B	2.44B	2.52B	2.79B	2.72B	2.12B
Operating Margin	13.4%	13.3%	12.5%	13.8%	15.9%	15.8%	12.8%
Income Before Tax (EBT)	2.77B	2.58B	2.36B	2.51B	2.88B	2.71B	2.09B
Interest Income	N/A	N/A	26.00M	N/A	34.00M	49.00M	36.00M
Interest Expense	450.00M	505.00M	542.00M	86.00M	40.00M	66.00M	88.00M
Other Income/Expense	6.00M	-44.00M	-74.00M	-10.00M	80.00M	-10.00M	-33.00M
Net Income	2.08B	1.99B	1.57B	1.92B	2.25B	13.85B	1.52B
Income Tax Expense	614.00M	531.00M	743.00M	563.00M	600.00M	652.00M	410.00M
Net Profit Margin	10.1%	10.1%	8.0%	10.4%	12.8%	80.7%	9.2%
EBITDA	3.34B	3.21B	3.04B	3.15B	3.42B	3.35B	2.78B
EBITDA Margin	16.2%	16.3%	15.6%	17.2%	19.4%	19.5%	16.7%
Depreciation & Amortization	578.00M	580.00M	610.00M	633.00M	625.00M	630.00M	659.00M
EPS Basic	4.56	4.37	3.04	4.22	4.90	4.41	3.35
EPS Diluted	4.55	4.34	3.02	4.22	4.90	4.41	3.35
Shares Outstanding	456.52M	456.00M	455.00M	453.93M	454.71M	454.71M	454.71M
Diluted Shares Outstanding	460.27M	459.00M	458.00M	453.93M	454.71M	454.71M	454.71M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.